Dexcom vs ResMed |
ResMed | reported revenue of $5.7 billion in fiscal 2026, 1.2 times Dexcom's $4.7 billion in fiscal 2025. Dexcom's revenue grew 15.6% in its latest year, and ResMed |'s grew 9.8%. Dexcom had an operating margin of 19.6%, against 33.4% at ResMed |. Free cash flow was $1.1 billion at Dexcom and $1.6 billion at ResMed |. Their fiscal years end in different months (December 31 and June 30), so the periods don't line up exactly.
Side by side
| Dexcom | ResMed | | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, Jun 30, 2026 |
| Revenue | $4.7B | $5.7B |
| Revenue growth | 15.6% | 9.8% |
| Revenue growth a year, last 5 years | 19.3% | 12.1% |
| Gross margin | 60.1% | 61.1% |
| Operating margin | 19.6% | 33.4% |
| Net margin | 17.9% | 26.9% |
| Free cash flow | $1.1B | $1.6B |
| Free cash flow margin | 23.1% | 29.2% |
| Return on capital | 44.9% | 26.7% |
| Net debt to EBITDA | −0.6x | −0.4x |
| Dividends and buybacks | $500M | $1.0B |
| Change in diluted share count | −1.7% | −0.9% |
| Last close | $78.57 | $253.20 |
| P/E at the last close | 31.2× | 24.3× |
| Insider trades, last 12 months | bought $1.0 million, sold $12.8 million | sold $22.4 million |
| Piotroski F-score | 8 of 9 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
DexcomResMed |
Operating margin
Percent of revenue
DexcomResMed |
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
DexcomResMed |